Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study.

Meyskens FL Jr, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD, et al.

J Clin Oncol. 1994 Oct;12(10):2060-5.

PMID:
7931474
2.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.

Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253.

3.

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.

Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C.

J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4.

PMID:
20048184
4.

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, Stratigos A.

Cochrane Database Syst Rev. 2015 May 16;(5):CD010307. doi: 10.1002/14651858.CD010307.pub2. Review.

PMID:
25978975
5.

Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.

Eggermont AM.

Recent Results Cancer Res. 2000;157:178-89. Review.

PMID:
10857171
6.

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.

Lancet Oncol. 2012 Jun;13(6):589-97. doi: 10.1016/S1470-2045(12)70138-9. Epub 2012 May 9.

PMID:
22575589
7.

[Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].

Kretschmer L, Helmbold P, Emmert S, Marsch WC.

Hautarzt. 2002 Aug;53(8):536-41. German.

PMID:
12221468
8.

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH.

J Clin Oncol. 1996 Jan;14(1):7-17.

PMID:
8558223
9.

Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival.

Retsas S, Quigley M, Pectasides D, Macrae K, Henry K.

Cancer. 1994 Apr 15;73(8):2119-30.

11.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M.

J Clin Oncol. 2004 Jan 1;22(1):53-61. Epub 2003 Dec 9.

PMID:
14665609
12.

Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma.

Kretschmer L, Preusser KP, Marsch WC, Neumann C.

Melanoma Res. 2000 Oct;10(5):483-9.

PMID:
11095410
13.

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V.

Cochrane Database Syst Rev. 2013 Jun 18;(6):CD008955. doi: 10.1002/14651858.CD008955.pub2. Review.

PMID:
23775773
14.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE.

J Clin Oncol. 2002 Apr 15;20(8):2058-66.

PMID:
11956266
15.
16.
17.

[Preventive lymph node excision in the treatment concept of melanoma of the extremities].

Binder J, Henneking K.

Zentralbl Chir. 1996;121(6):474-7. German.

PMID:
8767334
18.

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group..

Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20.

PMID:
21256809
19.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U.

J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.

PMID:
23008300
20.

Adjuvant irradiation for axillary metastases from malignant melanoma.

Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72.

PMID:
11958890

Supplemental Content

Support Center